Warren CJ et al.The antiviral restriction factors IFITM1, 2 and 3 do not inhibit infection of human papillomavirus, cytomegalovirus and adenovirus.PLoS One 9:e96579 (2014).
Krishnappa P et al.Expression of P16 in high-risk human papillomavirus related lesions of the uterine cervix in a government hospital, Malaysia.Diagn Pathol 9:202 (2014).
Day PM et al.A human papillomavirus (HPV) in vitro neutralization assay that recapitulates the in vitro process of infection provides a sensitive measure of HPV L2 infection-inhibiting antibodies.Clin Vaccine Immunol 19:1075-82 (2012).
Millán AF et al.Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva.Protein Expr Purif 74:1-8 (2010).
Johnson KM et al.Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus.J Virol 83:2067-74 (2009).
Fernández-San Millán A et al.Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic.Plant Biotechnol J 6:427-41 (2008).
Day PM et al.Mechanisms of human papillomavirus type 16 neutralization by l2 cross-neutralizing and l1 type-specific antibodies.J Virol 82:4638-46 (2008).
Steele JC et al.T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.Br J Cancer 93:248-59 (2005).
Zhang W et al.Expression of human papillomavirus type 16 L1 protein in Escherichia coli: denaturation, renaturation, and self-assembly of virus-like particles in vitro.Virology 243:423-31 (1998).
McLean CS et al.Production and characterisation of a monoclonal antibody to human papillomavirus type 16 using recombinant vaccinia virus.J Clin Pathol 43:488-92 (1990).